CSCI Stock Overview A specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
COSCIENS Biopharma Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for COSCIENS Biopharma Historical stock prices Current Share Price CA$3.00 52 Week High CA$11.10 52 Week Low CA$2.50 Beta 2.17 1 Month Change 20.00% 3 Month Change -18.92% 1 Year Change -61.54% 3 Year Change -91.26% 5 Year Change -97.50% Change since IPO -100.00%
Recent News & Updates
New minor risk - Share price stability Jan 03
New major risk - Market cap size Nov 20
Third quarter 2024 earnings released: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) Nov 14
COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors Oct 08
Cosciens Biopharma Inc. Announces Directorate Changes Oct 02
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT- Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency Aug 27 See more updates
New minor risk - Share price stability Jan 03
New major risk - Market cap size Nov 20
Third quarter 2024 earnings released: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) Nov 14
COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors Oct 08
Cosciens Biopharma Inc. Announces Directorate Changes Oct 02
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT- Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency Aug 27
Second quarter 2024 earnings released: US$0.64 loss per share (vs US$2.07 loss in 2Q 2023) Aug 15
Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director Jul 17 Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction. Jun 05
Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024 May 15 Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals. Dec 14
Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones Jul 14
Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk Aug 29
Aeterna Zentaris Announces Effective Date of Share Consolidation Jul 20
Aeterna slips ~10% after announcing date of reverse stock split Jul 19
Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022 Jul 07
Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022 Jun 22
Aeterna Zentaris Inc. Achieves Proof-Of-Concept for the Treatment of NMOSD with AIM Biologicals Program Jun 14
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (Macimorelin) for Diagnosing Adult Growth Hormone Deficiency May 26 Aeterna Zentaris Inc. Updates on Positive Pre-Clinical Results from Aim Biologicals Development Program for the Potential Treatment of Parkinson's Disease
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat May 12
Price target decreased to US$1.50 Apr 27
Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022 Apr 23
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 30
Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule Jan 27
Third quarter 2021 earnings released: US$0.014 loss per share (vs US$0.02 loss in 3Q 2020) Nov 06
Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.15 loss in 2Q 2020) Aug 06
Aeterna Zentaris Inc. Provides Update on Its Pre-Clinical and Clinical Development Programs Aug 05
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit Jun 04
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease) May 18
Aeterna Zentaris Inc. Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency May 14
Independent Director has left the company May 10
Aeterna Zentaris Announces the Selection of A Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism May 07
First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.036 profit in 1Q 2020) May 05
Aeterna Zentaris names Michael Teifel as chief scientific officer May 03
Full year 2020 earnings released: US$0.13 loss per share (vs US$0.34 loss in FY 2019) Mar 26
Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021 Mar 06
New 90-day high: US$1.08 Feb 05
Aeterna Zentaris Inc. Enters into an Exclusive Option Agreement to Evaluate Preclinical Potential COVID-19 Vaccine Developed at the Julius-Maximilians-University Wuerzburg Feb 03
Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53% Feb 02
Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics Jan 29
The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule Jan 28
New 90-day high: US$0.69 Jan 20
New 90-day high: US$0.51 Jan 05
Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin Dec 10
New 90-day high: US$0.44 Dec 02
Aeterna Zentaris Inc. Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin Nov 17
Third quarter 2020 earnings released: US$0.02 loss per share Nov 07
New 90-day low: US$0.33 Oct 29
The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc Oct 11
Aeterna Zentaris Inc. Announces Macimorelin Clinical Program Update Sep 17
New 90-day low: US$0.38 Sep 17
First half earnings released Aug 08
Aeterna Zentaris Inc. has completed a Follow-on Equity Offering in the amount of $7.000001 million. Aug 06
Aeterna Receives Nasdaq Warning on Minimum Price Jul 31
Aeterna Zentaris Inc. has completed a Composite Units Offering in the amount of $11.999087 million. Jul 08
Aeterna Zentaris Inc.(NasdaqCM:AEZS) dropped from Russell Microcap Value Index Jul 02 Shareholder Returns CSCI US Biotechs US Market 7D -5.7% -0.2% 3.2% 1Y -61.5% -7.0% 24.2%
See full shareholder returns
Return vs Industry: CSCI underperformed the US Biotechs industry which returned -7% over the past year.
Return vs Market: CSCI underperformed the US Market which returned 24.2% over the past year.
Price Volatility Is CSCI's price volatile compared to industry and market? CSCI volatility CSCI Average Weekly Movement 11.9% Biotechs Industry Average Movement 11.2% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: CSCI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CSCI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
Show more COSCIENS Biopharma Inc. Fundamentals Summary How do COSCIENS Biopharma's earnings and revenue compare to its market cap? CSCI fundamental statistics Market cap US$11.13m Earnings (TTM ) -US$23.21m Revenue (TTM ) US$4.83m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CSCI income statement (TTM ) Revenue US$4.83m Cost of Revenue US$668.00k Gross Profit US$4.17m Other Expenses US$27.38m Earnings -US$23.21m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -6.18 Gross Margin 86.18% Net Profit Margin -480.12% Debt/Equity Ratio 0%
How did CSCI perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/20 03:30 End of Day Share Price 2025/01/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources COSCIENS Biopharma Inc. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Douglas Loe Byron Capital Markets Douglas Loe Cantor Fitzgerald Canada Corporation Maher Yaghi Desjardins Securities Inc.
Show 13 more analysts 
